Related Experiment Videos
Are monotherapy options reasonable for T3 prostate cancer?
1Department of Urology and the Virginia Prostate Center of Eastern Virginia Medical School and Sentara Cancer Institute, Norfolk, USA.
Seminars in Urologic Oncology
|January 8, 1998
Summary
For clinical stage T3 prostate cancer, monotherapy with surgery, radiation, or hormones is insufficient. Combination therapy is recommended to improve outcomes and reduce treatment failure in prostate cancer management.
Area of Science:
- Oncology
- Urology
- Radiation Oncology
Background:
- Clinical stage T3 prostate cancer poses treatment challenges.
- Monotherapy with surgery, radiation, or hormonal treatments may be inadequate.
- Combination therapy is explored to improve treatment efficacy.
Purpose of the Study:
- To evaluate the effectiveness of monotherapy versus combination therapy for T3 prostate cancer.
- To analyze local and distant disease control in T3 prostate cancer treatment.
- To inform primary treatment strategies for advanced prostate cancer.
Main Methods:
- Review of treatment series reporting local and distant disease control.
- Analysis of outcomes for patients with clinical stage T3 prostate cancer.
- Comparative assessment of monotherapy and combination therapy approaches.
Main Results:
- Monotherapy (surgery, radiation, hormonal) is unlikely to be adequate alone for T3 prostate cancer.
- Combination therapies have shown promise in reducing local failure.
- Combination therapy trials indicate increased time to progression.
Conclusions:
- Primary treatment for T3 prostate cancer should involve combination therapy.
- Combination therapy can mitigate the impact of monotherapy failure.
- Further investigation into combination strategies is warranted for improved prostate cancer control.